Advaxis has announced that data from its ADXS-HER2 dose-escalation study in canine osteosarcoma (OSA) has been published in Clinical Cancer Research, an online publication of the American Association for Cancer Research (AACR) on March 18.
Advaxis is a clinical stage biotechnology company that develops cancer immunotherapies.
The ADXS-HER2 study was conducted by Nicola Mason, Ph.D., BVetMed, Associate Professor of Medicine at the University of Pennsylvania School of Veterinary Medicine. During the study, Dr. Mason assessed the immunogenicity, safety and impact of attenuated, recombinant Listeria monocytogenes (Lm) that was transformed with a HER2/Neu fusion protein (ADXS-HER2) on 18 dogs with surgically treated osteosarcoma and the animals’ survival. The study is part of the currently ongoing ADXS-HER2 clinical program.
Over the course of the study, the 18 dogs were given varying doses of ADXS-HER2 after the completion of surgery and chemotherapy. Within six months of the administered immunotherapy, 15 dogs showed an antigen-specific response. ADXS-HER2 reduced metastatic disease and extended the survival in comparison to a historical control group.
Osteosarcoma is a common form of bone tumor that is found in dogs. More than 10,000 dogs are diagnosed per year. Osteosarcoma is also common in children and teens.